Quotient Wealth Partners LLC Has $774,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Quotient Wealth Partners LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,210 shares of the medical instruments supplier’s stock after selling 122 shares during the period. Quotient Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $774,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its position in shares of Becton, Dickinson and Company by 277.3% during the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after purchasing an additional 1,423,353 shares during the period. PineStone Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after purchasing an additional 788,735 shares during the period. M&G Plc bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at about $173,692,000. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 32.5% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent research reports. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $2.34 during trading on Thursday, hitting $235.87. The stock had a trading volume of 209,608 shares, compared to its average volume of 1,403,409. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $266.29. The firm has a market cap of $68.17 billion, a price-to-earnings ratio of 52.47, a P/E/G ratio of 1.92 and a beta of 0.42. The business’s 50-day moving average is $236.49 and its 200 day moving average is $235.46.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the firm posted $2.96 EPS. The company’s revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.